Thomas William LeBlanc, MD

Associate Professor of Medicine
Associate Professor in Population Health Sciences
Member of the Duke Cancer Institute
Campus mail 2424 Erwin Road, Suite 602, Durham, NC 27705
Phone (919) 668-2115
Email address thomas.leblanc@duke.edu

I am a medical oncologist, palliative care physician, and patient experience researcher.  My clinical practice focuses on the care of patients with hematologic malignancies, with a particular emphasis on myeloid conditions and acute leukemias including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs / MPDs, CML).  

As founding Director of the Duke Cancer Patient Experience Research Program (CPEP), my research investigates common issues faced by people with cancer, including issues of symptom burden, quality of life, psychological distress, prognostic understanding, and treatment decision-making. This work aims to improve patients' experiences living with serious illnesses like blood cancers, including the integration of specialist palliative care services to provide an extra layer of support along with their comprehensive cancer care. More broadly, our team in CPEP conducts various studies of patient experience and outcomes issues in oncology, including retrospective chart review studies, comparative effectiveness work, prospective observational studies and registries, and qualitative research, along with efforts to facilitate the integration of patient-generated health data (PGHD) into routine cancer care processes, such as with electronic patient-reported outcome measures (ePROs) and other mobile health interventions (mHealth). 

This work has led to recognition as an "Inspirational Leader under 40" by the American Academy of Hospice and Palliative Medicine (AAHPM), "Fellow" status from the Academy in 2016, the 2018 international "Clinical Impact Award" from the European Association for Palliative Care, and the AAHPM "Early Career Investigator" award in 2020. I served as 2017-18 Chair of the ASCO Ethics Committee, and currently Chair the Scientific Review Committee of the NIH/NINR-funded Palliative Care Research Cooperative Group (PCRC; www.palliativecareresearch.org). I have served on various national guideline panels for AML and for palliative/supportive care issues in oncology, and was inducted as a Fellow of the American Society of Clinical Oncology (FASCO) in 2021. To date I have published over 150 Medline-indexed articles, and several chapters in prominent textbooks of oncology and palliative medicine.

Education and Training

  • Fellow, Medical Oncology, Duke University School of Medicine, 2012 - 2013
  • Fellowship, Hospice And Palliative Medicine, Duke University School of Medicine, 2011 - 2012
  • Chief Medical Resident, Duke University School of Medicine, 2010 - 2011
  • Resident, Duke University School of Medicine, 2007 - 2009
  • Intern, Duke University School of Medicine, 2006 - 2007
  • M.D., Duke University, 2006

Publications

Le, Hannah, Kellie Ryan, Svea K. Wahlstrom, Trudy Pendergraft, Martine C. Maculaitis, Oliver Will, Emily Mulvihill, and Thomas William LeBlanc. “Patient and physician decision-making on the use of novel agents in chronic lymphocytic leukemia (CLL): What drives preferences?” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Tabah, Ashley, Russell Knoth, David Huggar, Ronda M. Copher, Zhun Cao, Craig Lipkin, and Thomas W. Leblanc. “Examining Healthcare Resource Utilization (HCRU) and Costs in US Patients Diagnosed with Relapsed Acute Myeloid Leukemia (AML).” In Clinical Lymphoma Myeloma & Leukemia, 20:S181–S181, 2020.

Scholars@Duke

Tabah, Ashley, David Huggar, Brenna L. Brady, Krutika Jariwala-Parikh, Krystal Huey, Ronda M. Copher, and Thomas W. Leblanc. “The Economic Burden of Relapse in Acute Myeloid Leukemia (AML): A Retrospective Analysis of US Commercial and Medicare Claims.” In Clinical Lymphoma Myeloma & Leukemia, 20:S181–S181, 2020.

Scholars@Duke

Sekeres, Mikkael A., Gordon Guyatt, Gregory Abel, Shabbir Alibhai, Jessica K. Altman, Rena Buckstein, Hannah Choe, et al. “American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.” Blood Adv 4, no. 15 (August 11, 2020): 3528–49. https://doi.org/10.1182/bloodadvances.2020001920.

PMID
32761235
Full Text

Zaleta, Alexandra K., Melissa F. Miller, Julie S. Olson, Eva Y. N. Yuen, Thomas W. LeBlanc, Craig E. Cole, Shauna McManus, and Joanne S. Buzaglo. “Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma.” J Natl Compr Canc Netw 18, no. 8 (August 2020): 1087–95. https://doi.org/10.6004/jnccn.2020.7561.

PMID
32755984
Full Text

Porter, Laura, Thomas LeBlanc, Janet Bull, and Laura Hanson. “Caregiver-Guided Pain Management for Advanced Cancer: Results of a Randomized Controlled Trial.” In Journal of Pain and Symptom Management, 60:192–93, 2020.

Scholars@Duke

Hildenbrand, Jordan, Cheyenne Corbett, Debra Davis, Kris Herring, Susan Locke, Jesse Troy, Steve Wolf, et al. “Digital Supportive Care Awareness and Navigation (D-SCAN): Qualitative and Quantitative Results of a Pilot Randomized Trial in Patients with Advanced Cancer.” In Journal of Pain and Symptom Management, 60:272–272, 2020.

Scholars@Duke

Robles, Joanna, Jesse Troy, Kristin Schroeder, Paul Martin, and Thomas LeBlanc. “LIMITED ENGLISH PROFICIENCY IN PEDIATRIC STEM CELL TRANSPLANT: A RETROSPECTIVE AND QUALITATIVE STUDY.” In Pediatric Blood & Cancer, 67:S78–S78. WILEY, 2020.

Scholars@Duke

Pages